A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy

R. A. Previs, K. S. Bevis, W. Huh, Todd Tillmanns, L. Perry, K. Moore, J. Chapman, C. McClung, T. Kiet, J. Java, J. Chan, A. Alvarez Secord

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objective To develop a nomogram to predict overall survival (OS) in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy. Methods A multicenter retrospective study was conducted. Potential prognostic variables included age; stage; grade; histology; performance status; residual disease; presence of ascites and/or pleural effusions; number of chemotherapy regimens, treatment-free interval (TFI) prior to bevacizumab administration, and platinum sensitivity. Multivariate analysis was performed using Cox proportional hazards regression. The predictive model was developed into a nomogram to predict five-year OS. Results 312 women with recurrent ovarian cancer treated with bevacizumab and chemotherapy were identified; median age was 59 (range: 19-85); 86% women had advanced stage (III-IV) disease. The majority had serous histology (74%), high grade cancers (93.5%), and optimal cytoreductions (69.5%). Fifty-one percent of women received greater than two prior chemotherapeutic regimens. TFI (AHR = 0.98, 95% CI 0.97-1.00, p = 0.022) was the only statistically significant predictor in a multivariate progression-free survival (PFS) analysis. In a multivariate OS analysis, prior number of chemotherapy regimens, TFI, platinum sensitivity, and presence of ascites were significant. A nomogram to predict five-year OS was constructed and internally validated (bootstrap-corrected concordance index = 0.737). Conclusion Our multivariate model identified prior number of chemotherapy regimens, TFI, platinum sensitivity, and the presence of ascites as prognostic variables for OS in women with recurrent ovarian cancer treated with bevacizumab combined with chemotherapy. Our nomogram to predict five-year OS may be used to identify women who may benefit from bevacizumab and chemotherapy, but further validation is needed.

Original languageEnglish (US)
Pages (from-to)531-536
Number of pages6
JournalGynecologic Oncology
Volume132
Issue number3
DOIs
StatePublished - Jan 1 2014

Fingerprint

Nomograms
Ovarian Neoplasms
Drug Therapy
Survival
Platinum
Ascites
Survival Analysis
Histology
Pleural Effusion
Therapeutics
Bevacizumab
Multicenter Studies
Disease-Free Survival
Multivariate Analysis
Retrospective Studies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynecology

Cite this

A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy. / Previs, R. A.; Bevis, K. S.; Huh, W.; Tillmanns, Todd; Perry, L.; Moore, K.; Chapman, J.; McClung, C.; Kiet, T.; Java, J.; Chan, J.; Secord, A. Alvarez.

In: Gynecologic Oncology, Vol. 132, No. 3, 01.01.2014, p. 531-536.

Research output: Contribution to journalArticle

Previs, RA, Bevis, KS, Huh, W, Tillmanns, T, Perry, L, Moore, K, Chapman, J, McClung, C, Kiet, T, Java, J, Chan, J & Secord, AA 2014, 'A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy', Gynecologic Oncology, vol. 132, no. 3, pp. 531-536. https://doi.org/10.1016/j.ygyno.2014.01.036
Previs, R. A. ; Bevis, K. S. ; Huh, W. ; Tillmanns, Todd ; Perry, L. ; Moore, K. ; Chapman, J. ; McClung, C. ; Kiet, T. ; Java, J. ; Chan, J. ; Secord, A. Alvarez. / A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy. In: Gynecologic Oncology. 2014 ; Vol. 132, No. 3. pp. 531-536.
@article{cc325b8d7b5f478cb91f1638c418be85,
title = "A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy",
abstract = "Objective To develop a nomogram to predict overall survival (OS) in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy. Methods A multicenter retrospective study was conducted. Potential prognostic variables included age; stage; grade; histology; performance status; residual disease; presence of ascites and/or pleural effusions; number of chemotherapy regimens, treatment-free interval (TFI) prior to bevacizumab administration, and platinum sensitivity. Multivariate analysis was performed using Cox proportional hazards regression. The predictive model was developed into a nomogram to predict five-year OS. Results 312 women with recurrent ovarian cancer treated with bevacizumab and chemotherapy were identified; median age was 59 (range: 19-85); 86{\%} women had advanced stage (III-IV) disease. The majority had serous histology (74{\%}), high grade cancers (93.5{\%}), and optimal cytoreductions (69.5{\%}). Fifty-one percent of women received greater than two prior chemotherapeutic regimens. TFI (AHR = 0.98, 95{\%} CI 0.97-1.00, p = 0.022) was the only statistically significant predictor in a multivariate progression-free survival (PFS) analysis. In a multivariate OS analysis, prior number of chemotherapy regimens, TFI, platinum sensitivity, and presence of ascites were significant. A nomogram to predict five-year OS was constructed and internally validated (bootstrap-corrected concordance index = 0.737). Conclusion Our multivariate model identified prior number of chemotherapy regimens, TFI, platinum sensitivity, and the presence of ascites as prognostic variables for OS in women with recurrent ovarian cancer treated with bevacizumab combined with chemotherapy. Our nomogram to predict five-year OS may be used to identify women who may benefit from bevacizumab and chemotherapy, but further validation is needed.",
author = "Previs, {R. A.} and Bevis, {K. S.} and W. Huh and Todd Tillmanns and L. Perry and K. Moore and J. Chapman and C. McClung and T. Kiet and J. Java and J. Chan and Secord, {A. Alvarez}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.ygyno.2014.01.036",
language = "English (US)",
volume = "132",
pages = "531--536",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy

AU - Previs, R. A.

AU - Bevis, K. S.

AU - Huh, W.

AU - Tillmanns, Todd

AU - Perry, L.

AU - Moore, K.

AU - Chapman, J.

AU - McClung, C.

AU - Kiet, T.

AU - Java, J.

AU - Chan, J.

AU - Secord, A. Alvarez

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objective To develop a nomogram to predict overall survival (OS) in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy. Methods A multicenter retrospective study was conducted. Potential prognostic variables included age; stage; grade; histology; performance status; residual disease; presence of ascites and/or pleural effusions; number of chemotherapy regimens, treatment-free interval (TFI) prior to bevacizumab administration, and platinum sensitivity. Multivariate analysis was performed using Cox proportional hazards regression. The predictive model was developed into a nomogram to predict five-year OS. Results 312 women with recurrent ovarian cancer treated with bevacizumab and chemotherapy were identified; median age was 59 (range: 19-85); 86% women had advanced stage (III-IV) disease. The majority had serous histology (74%), high grade cancers (93.5%), and optimal cytoreductions (69.5%). Fifty-one percent of women received greater than two prior chemotherapeutic regimens. TFI (AHR = 0.98, 95% CI 0.97-1.00, p = 0.022) was the only statistically significant predictor in a multivariate progression-free survival (PFS) analysis. In a multivariate OS analysis, prior number of chemotherapy regimens, TFI, platinum sensitivity, and presence of ascites were significant. A nomogram to predict five-year OS was constructed and internally validated (bootstrap-corrected concordance index = 0.737). Conclusion Our multivariate model identified prior number of chemotherapy regimens, TFI, platinum sensitivity, and the presence of ascites as prognostic variables for OS in women with recurrent ovarian cancer treated with bevacizumab combined with chemotherapy. Our nomogram to predict five-year OS may be used to identify women who may benefit from bevacizumab and chemotherapy, but further validation is needed.

AB - Objective To develop a nomogram to predict overall survival (OS) in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy. Methods A multicenter retrospective study was conducted. Potential prognostic variables included age; stage; grade; histology; performance status; residual disease; presence of ascites and/or pleural effusions; number of chemotherapy regimens, treatment-free interval (TFI) prior to bevacizumab administration, and platinum sensitivity. Multivariate analysis was performed using Cox proportional hazards regression. The predictive model was developed into a nomogram to predict five-year OS. Results 312 women with recurrent ovarian cancer treated with bevacizumab and chemotherapy were identified; median age was 59 (range: 19-85); 86% women had advanced stage (III-IV) disease. The majority had serous histology (74%), high grade cancers (93.5%), and optimal cytoreductions (69.5%). Fifty-one percent of women received greater than two prior chemotherapeutic regimens. TFI (AHR = 0.98, 95% CI 0.97-1.00, p = 0.022) was the only statistically significant predictor in a multivariate progression-free survival (PFS) analysis. In a multivariate OS analysis, prior number of chemotherapy regimens, TFI, platinum sensitivity, and presence of ascites were significant. A nomogram to predict five-year OS was constructed and internally validated (bootstrap-corrected concordance index = 0.737). Conclusion Our multivariate model identified prior number of chemotherapy regimens, TFI, platinum sensitivity, and the presence of ascites as prognostic variables for OS in women with recurrent ovarian cancer treated with bevacizumab combined with chemotherapy. Our nomogram to predict five-year OS may be used to identify women who may benefit from bevacizumab and chemotherapy, but further validation is needed.

UR - http://www.scopus.com/inward/record.url?scp=84896388722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896388722&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2014.01.036

DO - 10.1016/j.ygyno.2014.01.036

M3 - Article

VL - 132

SP - 531

EP - 536

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -